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Abstract
Gastric cancer incidence has been steadily declining in countries with low frequencies of 
gastric carcinoma since early 1930s. In areas with higher incidences, the decline has been 
less obvious and slower. Nevertheless, gastric adenocarcinoma remains one of the most 
common causes of cancer‐related death worldwide. The poor outcome has been attributed 
to late detection of the condition, particularly in Americas and Europe, aggressive patho‐
genesis and lack of symptoms during early stages of the tumor development. In addition, 
sporadic stomach cancer mostly affects elderly individuals. In the majority of countries 
with low incidence, the average age at the disease presentation is above 65. Therefore, gas‐
tric adenocarcinoma, among other diseases associated with old age, raises health concerns 
in countries with changing demographic age profiles that show a trend of an increase in 
the proportion of the population aged over 60. The low 5‐year survival rate of patients 
underscores the critical need for the development of more accurate diagnostic tools and 
safe targeted chemotherapeutics. However, the heterogeneity of molecular changes rep‐
resents one of the most pressing issues in the current research of gastric cancer, impeding 
the translation of genetic aberrations into novel applications for medical practice.
Keywords: antineoplastic agent, cancer, chemotherapy, clinical trials, gastric 
adenocarcinoma, gastroesophageal junction adenocarcinoma, molecular heterogeneity, 
monoclonal antibodies, small‐molecule inhibitor, targeted therapy
1. Introduction
The incidence of gastric cancer (GC) has been declining globally in the last decades. This slow, yet 
steady decrease in incidence and mortality rates has been attributed to improved medical treat‐
ment of peptic ulcers and chronic gastritis, development of protocols for Helicobacter pylori eradi‐
cation, lifestyle changes, and introduction of safer food preservation methods [1, 2]. However, 
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it is also important to note that the total incidence of most common gastric malignancy, adeno‐
carcinoma, varies by geographic areas up to 20‐fold between the highest and the lowest risk 
populations. The high risk areas are in certain Asian regions, such as Japan, China and Korea, 
followed by Eastern Europe and some countries in South America [3]. Low‐risk populations 
are located in North America, India, the Philippines, most countries in Africa, some Western 
European countries and Australia [4]. Up to 10% of GCs arise as a consequence of inherited can‐
cer predisposition syndromes, such as Li‐Fraumeni syndrome, Lynch syndrome, Peutz‐Jeghers 
syndrome, hereditary breast and ovarian cancer, MUTYH‐associated adenomatous polyposis 
(MAP), familial adenomatous polyposis (FAP), juvenile polyposis syndrome and PTEN hamar‐
toma tumor syndrome (Cowden syndrome) [5, 6]. Genetic counselling and mutation analyses, 
regular endoscopic surveillance and screening of the at‐risk family members and risk‐reduc‐
tion surgery of stomach have greatly improved management of patients with hereditary muta‐
tions predisposing to the development of hereditary GC [5, 7]. However, approximately 90% 
of GCs are sporadic and typically occur in elderly population [6, 8]. Despite improvements 
in the diagnostic procedures, most cases of sporadic GCs are still detected at advanced stages 
due to the lack of specific symptoms associated with the early phases of tumor development. 
Consequently, high mortality rates attributable to advanced GC contribute significantly to the 
public health burden worldwide. The estimated overall 5‐year relative survival rates of patients 
with advanced GC in developed countries are still low, around 30% [9]. An additional reason for 
concern is the demographic transition to the older population accounting for the significant pro‐
portion of population in developed countries [10]. This demographic shift will have an impact 
on health services, as the number of people over the age of 65, who comprise the highest risk 
group for the development of sporadic GC, has been steadily increasing in these countries. The 
challenge most countries are facing at the present time is how to improve the healthy life expec‐
tancy with regard to early detection of chronic and degenerative diseases, including cancers.
2. From basic research to clinical needs
Research efforts have identified several risk factors, including environmental factors as well 
as epigenetic and genetic aberrations, which could be implicated in the initiation and progres‐
sion of gastric malignancies. Advances in high‐throughput technologies and bioinformatic 
systematic analyses have been complementing our knowledge of an intricate network of 
genetic and epigenetic changes associated with stomach carcinogenesis. Unfortunately, only 
a few of common mutations could be associated with the development of sporadic gastric 
adenocarcinomas, which is the most common type of GC in the non‐Asian world regions. 
In addition, breakthroughs in next‐generation sequencing and SNP profiling microarrays 
have revealed another dimension, contributing to the heterogeneity of cancers. Genetic back‐
ground, which affects the susceptibility for developing GC, could also be responsible for dif‐
ferences in responses to drugs and outcome measures evaluating survival, efficacy and safety 
of novel biological therapeutics in distinct populations.
Discovery‐oriented research performed in different world populations revealed that molecu‐
lar aberrations found in sporadic GCs do not correlate well with macroscopic and microscopic 
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classifications that are currently used in clinical practice for diagnosis and for rough assess‐
ment of the postoperative therapeutic management protocols [11]. For example, pathohis‐
tological Lauren classification, which is the most widely used diagnostic feature in clinical 
setting in Western countries, recognizes two main subtypes, intestinal and diffuse types of GC. 
Intestinal type of gastric adenocarcinoma is associated with intestinal metaplasia and tubular 
structures, whereas diffuse‐type carcinomas mostly consist of discohesive cells and/or signet 
ring cells. Two additional subtypes fall into this classification, if the tumors do not fit into 
two major subtypes clearly. Approximately 14% of tumors, exhibiting characteristics of intes‐
tinal and diffuse morphology, are classified as mixed type, whereas roughly 10% of gastric 
tumors, which display uncommon features, are allocated into indeterminate category [11–16]. 
It should also be noted that all adenocarcinomas show heterogeneity at the histological level. 
For example, even if tumors were histologically classified as intestinal or diffuse type, they 
are in fact often a mixture of several coexisting tissue types, including more or less well‐ 
developed tubular structures, poorly cohesive cells and signet ring cells, though one of these 
cell types usually predominates [17]. In the past, researchers have been focused on determin‐
ing distinct gene aberrations that could have been associated with these subtypes in order to 
constitute reliable biomarker panels, which would correlate with histological subtypes and 
indicate the likely course of disease progression. However, accumulating molecular data on 
GC aberrations revealed immense intertumor and intratumor heterogeneity of GCs [9, 18–21].
In recent years, molecular classifications, based on the results from high‐throughput tech‐
nologies, revealed the existence of different molecular subtypes regardless of pathohistologi‐
cal subtypes [17, 22–24]. The advantage of these novel classifications is that distinct aberrant 
molecular changes that characterize different subtypes could be exploited to develop novel 
treatment approaches. For example, the EBV subtype, recognized in the TCGA study, is 
defined by frequent amplification of JAK2, CD274 (PD‐L1) and PDCD1LG2 (PD‐L2) together 
with DNA hypermethylation and PIK3CA mutations [22]. Thus, patients with aberrations in 
PD‐1 signaling pathways could benefit from addition of pembrolizumab or other antibodies 
targeting PD‐1 axis [25]. Frequent occurrence of characteristic CpG island methylator pheno‐
types (CIMP) in GCs, particularly in association with H. pylori or Epstein‐Barr virus infection, 
could lead to introduction of epigenetic modulators into standard treatment regimens used 
against early and advanced forms of adenocarcinomas [22]. Deciphering molecular heteroge‐
neity of malignant gastric tumors and subsequent translation of this information into precision 
medicine or eventually into personalized medicine is the subject of several ongoing collabora‐
tive projects, such as The Cancer Genome Atlas (TCGA) based at the National Cancer Institute, 
the Cancer Genome Project at the Wellcome Trust Sanger Institute, and the International 
Cancer Genome Consortium, based at Ontario Institute for Cancer Research [22, 26–28].
However, the novelties of molecular classifications brought additional obstacles in transla‐
tional research. It has become evident that there is a gap between real clinical needs and cur‐
rent genetic research. The resources being put into high‐throughput identification of genetic 
and epigenetic changes accelerated the understanding of the molecular mechanisms underly‐
ing human diseases; however, the progression of this knowledge to patient benefit is lagging 
behind. In particular, surgical resection of stomach is still the main curative approach in the 
treatment of gastric cancer [29]. Although different types of nonsurgical treatment modalities, 
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including chemotherapy, radiation therapy, chemoradiation, as well as targeted therapies, 
have been evaluated in clinical studies and have been subsequently integrated in clinical set‐
ting, these regimens have not been internationally standardized and remain in the form of 
guidelines and recommendations [30]. In recent years, several roadmaps and initiatives have 
been established, with the aim to advance the knowledge transfer, promote collaborations 
between different scientific disciplines and medical environment, and determine the main 
obstacles, which hinder the progression and implementation of effective health care solu‐
tions [31–33]. The main recognized barriers have been associated with (i) the explosion of 
molecular research conducted by highly specialized scientists, (ii) the fragmented fields of 
biomedical research, (iii) the dynamics of basic research with regard to promotion, obtaining 
funding and grants, which resulted in separation of basic and clinically relevant research, 
(iv) differences in education and training, (v) lack of communication between clinicians and 
researchers and (vi) the separation of methodologies and infrastructure available in clinical 
environment and specialized molecular research laboratories [32, 33]. In addition, complex 
regulatory issues, associated with research ethical procedures and approvals and clearances 
of innovative biomedical devices or approaches, have been recognized as limiting factors in 
translational research [34]. One of the most pressing medical research problems in hetero‐
geneous diseases, such as GC, issuing from the accumulating research data, is the biological 
elucidation of molecular changes and how they affect processes and metabolic pathways in 
malignant cells. Although several molecular targets have been identified in complex diseases, 
only a few targeted therapies and other novel treatment approaches have been found to be 
effective in the management of malignant diseases. Another concern, which also has roots in 
underlying molecular changes driving the malignant phenotype, is the development of drug 
resistance, which results in therapeutic failure. Although multidisciplinary research efforts 
have identified main pathways as well as some specific genetic determinants implicated in 
this phenomenon, innate or acquired resistance of cancer cells remains a significant challenge 
of translational medicine [33, 34].
3. Targeted management of gastric cancer
Gastrointestinal malignancies are highly aggressive and currently used standard therapies 
showed only a modest effect on improving survival and preventing recurrence [35]. Targeted 
therapies, based on antibodies or small molecule compounds, targeting specific molecular 
aberrations associated with gastric tumors, could offer improved outcomes and potentially 
fewer adverse effects. In general, antibody‐based therapies are aimed against specific targets 
on the cell surface, whereas the design of small molecules is focused on their capacity to pen‐
etrate the cell membranes and target molecules inside cells.
3.1. Monoclonal antibodies
A number of monoclonal antibodies targeting different proteins, including EGFR, PD‐1 
(CD279), VEGF growth factor family, MET, and IGF‐1R, are currently being tested and evalu‐
ated in clinical trials (Table 1) [36–39].
Gastric Cancer88
Target Anticancer agent Approval status in EU or USA
EGFR Cetuximab Advanced colorectal cancers with wild‐type KRAS, 
EGFR‐expressing
Squamous cell carcinoma of the head and neck
Matuzumab Discontinued, no benefits
Nimotuzumab High‐grade gliomab (orphan status withdrawn in 2008)
Pancreatic cancerb
Panitumumab Metastatic colorectal cancer with wild‐type KRAS
CD3, EpCAM Catumaxomab Gastric cancerb
HER2 Ado‐Trastuzumab 
emtansine (T‐DM1)a
Advanced or metastatic breast cancer, HER2‐positive
Pertuzumab Breast cancer, HER2‐positive
Trastuzumab Breast cancer, HER2‐positive
Gastric cancer, HER2‐positive
Gastroesophageal junction adenocarcinoma, HER2‐positive
IGF1R/IGF1/IGF2 Robatumumab Terminated due to business reasons
HGF/MET Margetuximab Clinical trial (NCT02689284), recruiting participants, promising 
preliminary results
Onartuzumab Clinical trial (NCT01662869), MET‐positive gastric cancer
Rilotumumab Gastric cancer (orphan status)b, (HGF‐positive)
PD‐1 Atezolizumab Locally advanced or metastatic urothelial carcinomac
Metastatic nonsmall cell lung cancerc
Durvalumab Bladder cancer (in review for approval)c
Nivolumab Nonsmall cell lung cancer
Renal cell carcinoma
Hodgkin disease
Melanoma, BRAF V600 wild‐type or BRAFV600 mutation‐positive
Recurrent or metastatic squamous cell carcinoma of the head and 
neckc
Pembrolizumab Unresectable or metastatic melanoma
Metastatic squamous cell carcinoma of the head and neckc
Metastatic nonsmall cell lung cancer
VEGFR/VEGF Bevacizumab Metastatic colorectal cancer
Nonsquamous nonsmall cell lung cancer
Glioblastomac
Metastatic renal cell carcinoma with interferon alfac
Cervical cancer
Platinum‐resistant recurrent epithelial ovarian, fallopian tube or 
primary peritoneal cancer
Metastatic breast cancerb
Metastatic kidney cancerb
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The Phase III ToGA study (NCT01041404), which evaluated the addition of trastuzumab to 
chemotherapy for treatment of advanced gastric cancer and gastroesophageal junction (GEJ) 
cancer, was one of the first studies that clearly demonstrated the benefits of targeted ther‐
apy in a selected group of patients [40, 41]. Trastuzumab is a monoclonal antibody directed 
against HER2 (ERBB2, HER2/neu). Overexpression of HER2 was observed in approximately 
10–20% of gastric and GEJ cancer patients in different populations [42]. In ToGA study, the 
patients, who were eligible for the treatment, were selected after evaluation of HER2 expres‐
sion in tumor tissues using immunohistochemistry (IHC) or fluorescence in situ hybridiza‐
tion (FISH). The median overall survival was significantly improved in patients who received 
trastuzumab and cisplatin‐based chemotherapy in comparison with patients, who received 
only chemotherapy. In addition, further studies showed that the quality of life in HER2‐ 
positive patients, receiving trastuzumab in combination with chemotherapy, was improved 
and the toxicity burden was comparable to chemotherapy‐alone arm [43]. It was also observed 
that the time to deterioration and quality‐adjusted time without symptoms of disease or toxic‐
ity were prolonged in the trastuzumab‐chemotherapy arm. Additional post hoc exploratory 
analyses investigated the correlations between HER2 overexpression and clinical and epide‐
miological features of patients [44]. Interestingly, HER2 overexpression levels were similar 
in patients from Europe and Asia, whereas they were lower in patients from Central/South 
America. Overexpression or amplification of HER2 was more common in intestinal GCs than 
diffuse or mixed types of GC, which was in concordance with other studies [45, 46]. In addi‐
tion, GEJ tumors showed higher rate of HER2 overexpression or amplification than stomach 
tumors, indicating that GEJ adenocarcinoma differs in etiology and pathogenesis from distal 
stomach tumors. Evaluation of HER2 staining performance indicated great variability and 
the researchers concluded that ideally six to eight specimens should be collected in order to 
obtain accurate estimation of HER2‐positivity. HER2 testing and trastuzumab treatment have 
been integrated in clinical settings in several developed countries.
Ramucirumab is a monoclonal antibody, targeting angiogenesis‐related protein VEGFR2. It 
has been or is being evaluated in more than 20 clinical trials (NCT01246960, NCT01170663, 
NCT01983878, NCT02661971, NCT02314117, NCT00917384, NCT02934464 and so on) [47]. 
First published results demonstrated promising results for this biological drug, indicating 
that combination of ramucirumab with paclitaxel or platinum‐containing or fluoropyrimi‐
dine‐containing chemotherapy increases overall survival, progression‐free survival as well 
Target Anticancer agent Approval status in EU or USA
Ramucirumab Advanced gastric cancer
Nonsmall cell lung cancer
Metastatic colorectal cancer
aAntibody‐drug conjugate (ADC) of stably linked trastuzumab and potent microtubule inhibitor emtansine.
bOnly in Europe.
cOnly in USA.
Table 1. Antineoplastic monoclonal antibodies, currently being evaluated in clinical trials for the treatment of gastric 
cancer.
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as quality of life when compared to chemotherapy‐only arm [48–50]. In 2014, FDA approved 
the addition of ramucirumab to paclitaxel as the treatment for patients with advanced GC 
or GEJ adenocarcinoma as well as its use as monotherapy for patients who did not respond 
to the first‐line therapy with platinum‐ or fluoropyrimidine‐containing chemotherapy [51]. 
However, another Phase II study (NCT01246960), evaluating addition of ramucirumab to 
combined leucovorin, 5‐fluorouracil and oxaliplatin chemotherapy (FOLFOX), did not show 
an improvement of outcome measures, progression‐free survival and overall survival, in par‐
ticipants with gastric, esophageal and GEJ cancers [52].
Based on previous more or less promising results in the treatment of glioblastoma, colon, 
breast and lung cancers targeting angiogenesis with monoclonal antibody bevacizumab 
directed against VEGFA, Avagast clinical study was launched with the aim to evaluate the 
benefit of bevacizumab for GC patients [53–61]. Bevacizumab was added to the first‐line 
chemotherapy, consisting of cisplatin and capecitabine or fluorouracil (FU) [54]. The subse‐
quent unadjusted analyses demonstrated improved overall response rate and  progression‐
free survival in the bevacizumab‐cisplatin‐FU arm. Unadjusted overall survival rate did not 
reach statistical significance. The toxicity of the tested treatment was comparable with the 
placebo‐cisplatin‐FU chemotherapy as well as with previous findings in patients with colon 
cancer receiving similar treatment. Subgroup analyses demonstrated differences in the effi‐
cacy of bevacizumab addition to chemotherapy between examined populations. Efficacy was 
increased in Pan‐American and possibly European populations (the results were not clear), 
whereas Asian patients appeared to have no benefit from treatment with bevacizumab. The 
research group also observed regional differences in median overall survival and progression‐
free survival, which could be attributed to different factors, such as different distributions of 
tumor histological types in the examined populations, differences in administering subse‐
quent therapies and so on [54]. In a similar study, Avatar, which included patients from the 
China, the researchers also confirmed that patients receiving bevacizumab plus capecitabine‐
cisplatin did not show an improvement in overall survival and progression‐free survival, 
when compared to placebo arm [62]. Although the response rate was higher in bevacizumab 
arm, the difference was not significant. Inconsistencies in overall survival of patients receiving 
bevacizumab in addition to chemotherapy, prompted further research, focused on evaluating 
plasma and tumor biomarkers and clinical outcomes [63]. High plasma VEGFA levels were 
associated with better overall survival, progression‐free survival and overall response rate in 
the group of patients with high plasma VEGFA levels, receiving bevacizumab‐cisplatin‐FU 
therapy, in comparison with patients with low plasma VEGFA levels. Interestingly, the ben‐
eficial effect of bevacizumab in these patients with regard to two measured indicators, overall 
survival and progression‐free response, was more prominent in non‐Asian patients, whereas 
in Asian patients, the effect was not significant. In addition, a weak association between low 
levels of tumor neuropilin‐1 expression and better overall survival, progression‐free survival 
and overall response rate was observed in a group of patients, receiving bevacizumab, com‐
pared to patients who had high expression of neuropilin‐1. In conclusion, both VEGFA and 
neuropilin‐1 are promising predictive biomarkers for selection of patients who would benefit 
from addition of bevacizumab to standard chemotherapy, although, as researchers noted, 
more thorough investigations to further characterize these markers are needed [63].
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A preliminary investigation Phase 1b KEYNOTE‐012 (NCT01848834) of selected patients with 
GC or esophageal cancer who were PD‐1L positive showed that this population of patients 
could benefit from treatment with pembrolizumab, a monoclonal IgG4 antibody designed to 
block the interaction between PD‐1 (CD279) and its ligands PD‐L1 (CD274) and PD‐L2 [64]. 
PD‐1L is one of two known ligands for PD‐1 receptor that is implicated in downregulation of 
the immune system by terminating T cell activation [65]. PD‐1L has been relatively frequently 
(from 25 to 65%) found overexpressed in gastric epithelial cells as well as in tumor infiltrating 
cells [66–69]. Activation of PD‐1 axis is associated with tumor‐induced immune suppression 
[70]. PD‐1 overexpression has been less well characterized. Investigation of the expression of 
several immune checkpoint molecules, including PD‐1 in peripheral blood mononuclear cells 
of patients with gastric adenocarcinoma prior to and after the surgery, showed that expres‐
sion of PD‐1 was upregulated on CD4+ and CD8+ T cells after surgery, reaching peaks on the 
days 1 and 7 after surgery, respectively [71]. The frequencies of PD‐1+CD4+ and PD‐1+CD8+ 
cells reached preoperative levels after approximately 30 days after the surgery, indicating 
that surgery stress suppresses immune activity and could promote immune evasion of tumor 
and metastatic cells [71]. In particular, this mechanism could affect the ability of circulating 
tumor cells, which are shed from primary tumor mass, to evade immune system and estab‐
lish secondary tumor niches. Another study also confirmed significantly higher expression of 
PD‐1 on T cells obtained from blood and tumor tissues in patients with GC, when compared 
to normal gastric tissues from controls [72]. In KEYNOTE‐012 study, the overall response rate 
to treatment with pembrolizumab was 32% in Asian patients and 30% in non‐Asian patients. 
The researchers also observed that significant associations existed between progression‐free 
survival, overall response rate and PD‐1L expression. Further analyses showed that overall 
response was 22% for all enrolled patients, although all responses were partial responses. It 
should be noted that this study was preliminary, the number of tested patients was small and 
the majority of patients had prior to enrolment in this study received two or more systemic or 
adjuvant therapies. The researchers also observed that although no treatment‐related deaths 
occurred, four patients had to terminate the treatment due to immune‐mediated toxic effects 
[25]. Further studies are currently being carried out in order to assess the safety, tolerability 
and antitumor activity of pembrolizumab in patients with GC (NCT02335411, NCT02370498, 
NCT02494583, and NCT02443324). In addition, the downregulation of activated T cells imme‐
diately after surgery through PD‐1 signaling pathway, as demonstrated in one study [71], 
could be further explored to assess the benefit of administering PD‐1 blocking antibodies 
prior to or immediately after surgery.
Rilomet‐1 (NCT01697072) study attempted to evaluate the addition of rilotumumab to 
standard cisplatin and capecitabine chemotherapy as a first‐line therapy for patients with 
advanced MET‐positive GC or GEJ adenocarcinoma [73, 74]. Rilotumumab is a human mono‐
clonal antibody against c‐MET (HGFR) factor. HGF is the only known ligand for HGFR or 
c‐MET, a tyrosine kinase receptor, which has been found to be frequently overexpressed 
in tumor gastric tissues [75–80]. Although the first results were promising, showing trends 
toward improved survival of patients, all trials with this compound were later terminated, 
due to unexpected deaths of patients in the rilotumumab‐chemotherapy arm compared with 
the chemotherapy‐alone arm in one of the trials [81].
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3.2. Small‐molecule compounds
In 2010, FDA approved lapatinib, a small‐molecule tyrosine kinase inhibitor of EGFR and 
HER2, for the treatment of HER2‐positive breast cancer. Studies on gastric cell lines confirmed 
its antiproliferative activity [82]. Several clinical trials attempted to evaluate its effectivity 
and toxicity in patients with HER2‐positive GC (NCT02015169, NCT00313599, NCT00447226, 
NCT00103324, NCT00680901, NCT00486954, NCT01123473 and so on). Currently, the results 
are still inconclusive, due to termination of some of these studies or negative results regarding 
the lapatinib efficacy. For example, in Phase II study (NCT01145404), which recruited HER2‐
positive patients with advanced GC, who have previously failed first‐line platinum‐based 
therapy, lapatinib addition to capecitabine or lapatinib monotherapy did not show improve‐
ments in overall survival and response rates and the study was prematurely terminated [83]. 
Nevertheless, interesting conclusions could be drawn from the observations from two larger 
studies involving lapatinib testing. A multinational randomized clinical trial, TRIAL‐013/
LOGiC (NCT00680901), investigated the benefit of the lapatinib addition to capecitabine‐
oxaliplatin (CapeOx) chemotherapy, administered to HER2‐positive patients with locally 
advanced, unresectable, or metastatic gastric, esophageal, or GEJ cancer [45]. A total of 545 
eligible patients were evaluated, and lapatinib efficacy analyses were performed in a group 
consisting of 454 patients with FISH confirmed amplification of HER2 (primary efficacy popu‐
lation, PEP). The underlying reason for this stratification was based on the results of previous 
studies performed on breast cancer patients, which showed that lapatinib administration ben‐
efits only a selected population of patients with HER2 amplification, regardless of the status 
of HER2 expression, determined with IHC [84]. Although the lapatinib addition to CapeOX 
did not improve overall survival in PEP and neither in the group of total eligible patients, 
there was significant improvement of progression‐free survival in PEP. Additional analyses 
revealed that lapatinib was more effective in Asian patients and younger patients. In addi‐
tion, lapatinib was less effective in patients, who had undergone gastrectomy with pylorus 
removed, than in patients with intact pylorus [45]. Based on these results, the authors did not 
recommend the use of lapatinib in combination with CapeOx in patients with HER2‐positive 
GC [45]. In a TyTAN Phase III (NCT00486954) clinical trial, which included Asian patients, 
lapatinib addition to paclitaxel chemotherapy also did not significantly improve median 
overall survival and progression‐free survival [85]. Lapatinib benefit was observed a small 
group of patients, whose gastric tumors were both FISH positive and had a score of 3+ in IHC 
evaluation. In addition, population stratification analyses showed that Chinese patients in 
the lapatinib arm had significantly improved overall survival and progression‐free survival. 
Preliminary pharmacokinetic analyses performed as a part of trial revealed that lapatinib 
or lapatinib‐paclitaxel administration could result in different plasma concentrations of the 
drugs. Furthermore, both AUC
0‐24
 (area under the concentration‐time curve from time 0 to 
24 h) and maximum plasma concentration of lapatinib were lower in patients with pylorus 
removed than in patients with intact pylorus [85].
The underlying causes of clinical outcomes associated with lapatinib administration and 
HER2 gene amplification levels were further thoroughly investigated in TRIAL‐013/LOGiC 
cohort of patients [86]. Another group of upper gastrointestinal cancers, consisting of 419 
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(86%) gastric, 43 (8.8%) GEJ, and 26 (5.3%) esophageal cancers, obtained from commercial 
providers, was subsequently included for HER2 testing and analyses. This group was used to 
evaluate the concordance between different HER2 assay methods, which were performed in 
two central laboratories and local laboratory. The researchers observed high agreement rates 
between two different FISH methods, FDA‐approved Dako HER2 IQFISH pharmDx FISH 
assay and PathVysion HER2 FISH assay (Abbott Molecular, Inc.), for detecting HER2 ampli‐
fication. The concordance rate was also high (95%) between two central laboratories when 
evaluating results of FISH assays, whereas the concordance between local and central labora‐
tories was 87%. Expression of HER2 was tested using the FDA‐approved IHC test HercepTest 
(Dako Biotechnology). Comparison of local laboratory and central laboratory HER2 testing 
using IHC assay for the assessment of HER2 status in patients assigned to TRIO‐013/LOGiC 
trial showed that the concordance rate was less than 50%. Comparison of agreement between 
IHC and FISH assays in central laboratories showed 88% overall agreement for cases from the 
commercially obtained upper gastrointestinal carcinomas and 91% for the TRIO‐013/LOGiC 
cohort. Additional analyses confirmed the findings of Hecht and colleagues [45] that progres‐
sion‐free survival as well as overall survival was significantly higher in selected groups of 
patients, such as Asian patients and younger patients [45, 86]. These findings correlated well 
with the fact that these patients had higher levels of HER2 gene amplification. Interestingly, 
other studies also reported similar outcomes in GC patients with high HER2 amplification sta‐
tus when treated with monoclonal antibody trastuzumab [87, 88]. These findings pointed out 
clinically important aspect, which could underlie the discrepancy between studies and clini‐
cal trials, evaluating the benefit of anti‐HER2 targeted chemotherapies. First, HER2 expres‐
sion patterns differ between GC and breast cancer and furthermore, in GC the expression 
patterns are frequently heterogeneous [44, 46, 86, 88]. The optimal cutoff for selecting patients 
with GC who would benefit from addition of lapatinib to chemotherapy should be evaluated 
in further studies; however, at present, the results indicated that the cutoff value, based on 
FISH assays, could be the ratios 5.01–10.0 and >10.0 [86]. Second, it was also recognized that 
other alterations could affect the treatment with lapatinib. For example, it was established 
that in trastuzumab‐resistant breast and esophagogastric cancers, MET amplification could 
contribute to intrinsic or treatment‐acquired resistance to trastuzumab [89, 90]. Studies of 
breast and lung cancers have indicated that overexpression of other tyrosine kinases, includ‐
ing IGF‐1R, other members of HER family, and EphA2, could lead to development of resis‐
tance mechanisms against anti‐HER2 drugs, by bypassing anti‐HER2 inhibition of MAPK and 
PI3K/Akt signaling pathways [91, 92]. Therefore, additional studies, focusing on molecular 
biomarkers for selection of eligible patients for anti‐HER2 therapy, could improve the efficacy 
and safety of small molecular HER2 inhibitors as well as the safety of anti‐HER2 antibodies.
Several other small molecule inhibitors, which have been approved for use in treatment of 
other cancers, are being tested in clinical studies. For example, sunitinib, which inhibits cel‐
lular signaling by targeting PDGFRs and VEGFRs, has been evaluated as safe for treatment of 
GC patients in a few Phase I studies; however, Phase II studies have not confirmed its efficacy 
and benefit [93–96]. The safety and benefit of apatinib, which selectively inhibits VEGFR2, 
have been shown in Phase II and Phase III clinical trials [97, 98]. However, recent reports from 
other studies have raised concerns regarding the toxicity of apatinib, since it has shown toxic‐
ity in previous studies on patients with metastatic triple‐negative breast cancer [99].
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4. Conclusion
In recent years, only two targeted therapeutics, trastuzumab and ramucirumab, have been 
approved in Western countries for treatment of advanced GC, which is less than the num‐
ber of approved biological drugs for use in other common cancers. Several reasons could be 
responsible for that. First, although the explosion of knowledge on molecular mechanisms 
involved in human diseases has led to novel perspectives in medical treatment and diagnos‐
tic procedures, it appears that the enormous amount of molecular and biological informa‐
tion and the complexity of bioinformatic approaches, used to decipher the experimental data, 
in reality impede the transition from basic research to clinical applications. Second, clinical 
trials as well as basic research, utilizing novel high‐throughput techniques, revealed great 
heterogeneity among populations. The consequences of interracial differences are particu‐
larly evident in the field of developing novel small‐molecule drugs and antibodies. Genetic 
background in populations appears to account for unequal effectiveness and different safety 
profiles of targeted therapies in different population [100]. In addition, intratumor heteroge‐
neity found within individuals further complicates the development of effective drugs. There 
is common consensus that novel molecular determinants should be investigated in order to 
establish genetic profiles, which would enable the identification of the patient subpopula‐
tions, in which the treatment with targeted anti‐cancer agents would be most effective and 
beneficial. The first milestone in this process involves determination of different genetic land‐
scapes of GCs across the world, followed by tight collaborations between researchers, health‐
care practitioners and pharmaceutical companies. In addition, bioinformatic exploitation of 
biomedical data collected in databases and utilization and aggregation of already available 
research data from clinical studies and basic research could provide additional opportunities 
to identify disease‐specific genetic profiles and establish suitable prognosis prediction models, 
which could guide personalized treatment management.
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